Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, 2835, 2023)

被引：0

作者：

Kirkwood, John M. ^{[1
]}

Del Vecchio, Michele ^{[2
]}

Weber, Jeffrey ^{[3
]}

Hoeller, Christoph ^{[4
]}

Grob, Jean-Jacques ^{[5
]}

Mohr, Peter ^{[6
]}

Loquai, Carmen ^{[7
]}

Dutriaux, Caroline ^{[8
]}

Chiarion-Sileni, Vanna ^{[9
]}

Mackiewicz, Jacek ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Arenberger, Petr ^{[12
]}

Quereux, Gaelle ^{[13
]}

Meniawy, Tarek M. ^{[14
]}

Ascierto, Paolo A. ^{[15
]}

Menzies, Alexander M. ^{[16
]}

Durani, Piyush ^{[17
]}

Lobo, Maurice ^{[17
]}

Campigotto, Federico ^{[17
]}

Gastman, Brian ^{[18
]}

Long, Georgina V. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Hillman Canc Ctr, Pittsburgh, PA 15232 USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Med Univ Wien, Vienna, Austria

[5] Hop La Timone, Marseille, France

[6] Elbe Klinikum Buxtehude, Buxtehude, Germany

[7] Univ Med Ctr Mainz, Mainz, Germany

[8] Hop St Andre, Bordeaux, France

[9] Ist Oncol Veneto, IOV IRCCS, Padua, Italy

[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland

[11] Mar Sklodowska Curie Natl Res Inst Oncol, Gynecol Oncol, Warsaw, Poland

[12] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Cardiol, Prague, Czech Republic

[13] Nantes Univ Hosp, Nantes, France

[14] Univ Western Australia, Sir Charles Gairdner Hosp, Perth, WA, Australia

[15] Ist Nazl Tumori IRCCS Fondaz G Pascale, Naples, Italy

[16] Univ Sydney, Royal North Shore & Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Cleveland Clin, Cleveland Hts, OH USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02775-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：906 / 906

页数：1

共 50 条

[21] A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
Vreeland, Timothy J.
Clifton, Guy T.
Hale, Diane F.
Chick, Robert C.
Hickerson, Annelies T.
Cindass, Jessica L.
Adams, Alexandra M.
Bohan, Phillip M. Kemp
Andtbacka, Robert H. I.
Berger, Adam C.
Jakub, James W.
Sussman, Jeffrey J.
Terando, Alicia M.
Wagner, Thomas
Peoples, George E.
Faries, Mark B.
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (11) : 6126 - 6137
[22] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Weber, J.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance Fernandez, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J-J.
Sileni, V. Chiarion
Marquez-Rodas, I.
Butler, M. O.
Maio, M.
Middleton, M.
de la Cruz Merino, L.
Lobo, M.
de Pril, V.
Larkin, J.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2020, 31 : S731 - S732
[23] Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Zimmer, Lisa
Livingstone, Elisabeth
Hassel, Jessica C.
Fluck, Michael
Eigentler, Thomas
Loquai, Carmen
Haferkamp, Sebastian
Gutzmer, Ralf
Meier, Friedegund
Mohr, Peter
Hauschild, Axel
Schilling, Bastian
Menzer, Christian
Kieker, Felix
Dippel, Edgar
Rosch, Alexander
Simon, Jan-Christoph
Conrad, Beate
Korner, Silvia
Windemuth-Kieselbach, Christine
Schwarz, Leonora
Garbe, Claus
Becker, Juergen C.
Schadendorf, Dirk
LANCET, 2022, 400 (10358): : 1117 - 1129
[24] Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
Yokota, Kenji
Uchi, Hiroshi
Uhara, Hisashi
Yoshikawa, Shusuke
Takenouchi, Tatsuya
Inozume, Takashi
Ozawa, Kentaro
Ihn, Hironobu
Fujisawa, Yasuhiro
Qureshi, Anila
de Pril, Veerle
Otsuka, Yasushi
Weber, Jeffrey
Yamazaki, Naoya
JOURNAL OF DERMATOLOGY, 2019, 46 (12): : 1197 - 1201
[25] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Luke, Jason J.
Rutkowski, Piotr
Queirolo, Paola
Del Vecchio, Michele
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
de la Cruz-Merino, Luis
Khattak, Muhammad A.
Schadendorf, Dirk
Long, Georgina, V
Ascierto, Paolo A.
Mandala, Mario
De Galitiis, Federica
Haydon, Andrew
Dummer, Reinhard
Grob, Jean-Jacques
Robert, Caroline
Carlino, Matteo S.
Mohr, Peter
Poklepovic, Andrew
Sondak, Vernon K.
Scolyer, Richard A.
Kirkwood, John M.
Chen, Ke
Diede, Scott J.
Ahsan, Sama
Ibrahim, Nageatte
Eggermont, Alexander M. M.
LANCET, 2022, 399 (10336): : 1718 - 1729
[26] UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067)
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean-Jacques
Cowey, C. Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier F.
Smylie, Michael
Dummer, Reinhard
Hill, Andrew
Haanen, John
Maio, Michele
McArthur, Grant
Walker, Dana
Jiang, Joel
Horak, Christine
Larkin, James
Hodi, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 127 - 128
[27] Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
Motzer, Robert J.
Bex, Axel
Russo, Paul
Tomita, Yoshihiko
Cutuli, Hernan
Rojas, Carlos
Gross-Goupil, Marine
Schinzari, Giovanni
Melichar, Bohuslav
Barthelemy, Philippe
Garcia, Abraham Ruiz
Sosman, Jeffrey A.
Grimm, Marc-Oliver
Goh, Jeffrey C.
Suarez, Cristina
Kollmannsberger, Christian K.
Simsek, Burcin
Spiridigliozzi, Julia
Lee, Chung-Wei
Grunwald, Viktor
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : LBA358 - LBA358
[28] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
Long, Georgina, V
Luke, Jason J.
Khattak, Muhammad A.
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Mohr, Peter
Dummer, Reinhard
Gershenwald, Jeffrey E.
Yoon, Charles H.
Wu, Xi Lawrence
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Ascierto, Paolo A.
LANCET ONCOLOGY, 2022, 23 (11): : 1378 - 1388
[29] ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP
Besse, Benjamin
Mazieres, Julien
Ribassin-Majed, L.
Barlesi, Fabrice
Bennouna, Jaafar
Gervais, Radj
Moreau, Lionel
Berard, Henri
Debieuvre, Didier
Molinier, Olivier
Moro-Sibilot, Denis
Souquet, Pierre-Jean
Pignon, Jean-Pierre
Amour, Elodie
Celebic, A.
Morin, Franck
Milleron, Bernard
Zalcman, Gerard
Soria, Jean-Charles
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S301 - S301
[30] Adjuvant pazopanib or placebo in resected stage I NSCLC patients: Results of the NSCLC adjuvant randomized phase II trial (IFCT0703) from the French collaborative Intergroup
Besse, B.
Mazieres, J.
Pignon, J. P.
Bennouna, J.
Barlesi, F.
Gervais, R.
Amour, E.
Morin, F.
Zalcman, G.
Soria, J. C.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S9 - S9

← 1 2 3 4 5 →